Trials / Completed
CompletedNCT02379910
A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis
AM1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- AnaMar AB · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AM1030-CREAM or placebo |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2015-03-05
- Last updated
- 2015-12-11
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02379910. Inclusion in this directory is not an endorsement.